Loading...
XNAS
MNOV
Market cap67mUSD
Jul 09, Last price  
1.38USD
1D
-1.43%
1Q
-7.38%
Jan 2017
-77.11%
IPO
-88.60%
Name

MediciNova Inc

Chart & Performance

D1W1MN
XNAS:MNOV chart
P/E
P/S
165.81
EPS
Div Yield, %
Shrs. gr., 5y
2.01%
Rev. gr., 5y
%
Revenues
410k
263,877263,877,0000000802,5806,003,25700000004,037,49901,000,0000409,657
Net income
-12m
L+8.58%
-35,689,611-48,903,244-21,924,829-20,368,890-20,187,308-17,734,076-10,961,314-4,028,528-9,195,292-8,845,079-10,865,979-11,163,136-14,675,087-12,941,658-13,853,897-10,134,252-14,069,083-8,571,516-11,049,549-11,997,957
CFO
-10m
L-7.83%
-34,059,023-43,858,689-21,118,380-17,014,162-17,698,079-13,308,652-11,864,438-10,646,456816,529-7,152,370-6,546,213-6,923,934-9,114,121-9,124,987-10,826,362-9,381,605-12,911,563-7,431,038-10,642,964-9,810,061

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.
IPO date
Dec 01, 2006
Employees
13
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT